Aurobindo Pharma Limited — Updates, 29-08-2025: General Updates
29-08-2025 | 10:07 pm
29-08-2025 | 10:07 pm
Aurobindo Pharma's subsidiary Apitoria Pharma received 5 procedural US FDA observations for its API unit. Importantly, no data integrity issues were reported, and the company states no financial or operational impact. They plan to respond to the FDA.
No comments yet. Be the first to comment!
